2022
DOI: 10.3390/jcm11133879
|View full text |Cite
|
Sign up to set email alerts
|

A Review of Selective Laser Trabeculoplasty: “The Hype Is Real”

Abstract: Presently, there is no efficacious treatment for glaucomatous optic neuropathy; the current treatment is focused on lowering intraocular pressure (IOP). Studies have demonstrated the safety and efficacy of selective laser trabeculoplasty (SLT) in reducing the IOP in eyes with open-angle (OAG) glaucoma or ocular hypertension (OH). Moreover, the European Glaucoma Society has instated SLT as the first-line or adjunctive treatment in OAG or OH, reiterating its clinical significance. In this review, we outline the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
13
0
5

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(19 citation statements)
references
References 122 publications
1
13
0
5
Order By: Relevance
“…Recent research has underscored the safety and effectiveness of SLT as an initial treatment option for glaucoma [ 29 , 30 ]. The European Glaucoma Society now recognizes SLT as either a primary or supplementary treatment for open-angle glaucoma and ocular hypertension, highlighting its clinical importance [ 31 , 32 ]. In Australia, while glaucoma medication prescriptions reached their highest in 2015, there was a subsequent decrease of 14.9% by 2017 [ 33 ].…”
Section: Discussionmentioning
confidence: 99%
“…Recent research has underscored the safety and effectiveness of SLT as an initial treatment option for glaucoma [ 29 , 30 ]. The European Glaucoma Society now recognizes SLT as either a primary or supplementary treatment for open-angle glaucoma and ocular hypertension, highlighting its clinical importance [ 31 , 32 ]. In Australia, while glaucoma medication prescriptions reached their highest in 2015, there was a subsequent decrease of 14.9% by 2017 [ 33 ].…”
Section: Discussionmentioning
confidence: 99%
“…Nuestro estudio demostró una reducción estadísticamente significativa de los valores de PIO, tanto a los 6 como a los 12 meses, alcanzando reducciones promedio de un 13 y un 15% respectivamente (p < 0.0001 y p < 0.0002). Estas reducciones estarían dentro de los valores publicados en un reciente metaanálisis, en donde se describen series con descensos que van desde un 6.9 a un 35% a los 12 o más meses de seguimiento [7][8][9][10][11] .…”
Section: Discussionunclassified
“…La SLT ha demostrado ser muy efectiva y con pocos efectos adversos, por lo que es una alternativa terapéutica inicial y que permite retrasar y/o reemplazar el tratamiento con colirios en promedio de 3 a 3.5 años 5 . Especial utilidad tiene en pacientes que no desean o no pueden usar gotas o en aquellos en los que la adherencia al tratamiento es el principal factor de riesgo para la progresión [4][5][6][7] . Además se puede repetir en pacientes que previamente hayan respondido, prolongando por más tiempo su efectividad 5 .…”
Section: Introductionunclassified
See 1 more Smart Citation
“…A parameter \begin{document}\gamma\end{document} is defined as post-SLT divided by pre-SLT trabecular outflow facility (i.e., the factor by which trabecular outflow facility increases following the procedure), which is estimated to be 50% based on previous clinical data [ 15 , 16 ]. It should be noted that the rationale behind increasing the trabecular outflow facility is the fact that the mechanism by which SLT lowers IOP is based on the principle of selective photothermolysis of pigmented cells of the trabecular meshwork targets without causing thermal damage to adjunctive structures [ 3 , 17 ]. Based on its mechanism, it may also be reasonable to assume that SLT does not affect any other parameters apart from \begin{document}C_o\end{document} .…”
Section: Methodsmentioning
confidence: 99%